Researchers have proposed a unifying mathematical framework that helps explain why many successful multimodal AI systems work ...

VANCOUVER, British Columbia--(BUSINESS WIRE)--Variational AI, the company behind Enki™, an advanced foundation model for small molecule drug discovery, today ...

Merck & Co. has doubled down on its partnership with Variational AI, striking a deal worth up to $349 million to collaborate on small molecule candidates against two targets. Variational disclosed a ...

VANCOUVER, British Columbia, September 23, 2025--(BUSINESS WIRE)--Variational AI, Inc., a generative AI drug discovery company, today announced a collaboration with Merck, known as MSD outside of the ...

Merck & Co. is taking a look at a generative AI platform. As an early user of Variational AI’s technology, the Big Pharma will assess the ability of the platform to generate novel small molecules that ...

Variational AI CEO Handol Kim's company has a platform that uses the language of chemistry to create drug recipes | Rob Kruyt Multinational drug developer Merck is partnering with a Vancouver-based ...

Generating synthetic data is useful when you have imbalanced training data for a particular class, for example, generating synthetic females in a dataset of employees that has many males but few ...

MSD has signed an agreement with Variational AI to use its generative AI (genAI) platform Enki in the discovery of new small-molecule medicines. Vancouver, Canada-based Variational – which emerged in ...